NCT02837991 - A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 16, 2018

Study Completion Date

November 16, 2018

Conditions

Renal Cell Carcinoma (RCC)Clear-cell Renal Cell CarcinomaPapillary Renal Cell CarcinomaKidney NeoplasmsMetastatic Renal Cell CarcinomaOvarian Clear Cell Carcinoma

Interventions

DRUG

CDX-014

Trial Locations (5)

14263

Roswell Park Cancer Institute, Buffalo

84112

Huntsman Cancer Institute, Salt Lake City

85258

HonorHealth Research Institute, Scottsdale

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

02215

Dana Farber Cancer Institute, Boston